US 20050031585A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2005/0031585 A1**

Hsu (43) **Pub. Date: Feb. 10, 2005**

(54) **METHOD FOR TREATING HEPATITIS C VIRUS INFECTION IN TREATMENT FAILURE PATIENTS**

(76) Inventor: **Henry H. Hsu**, Hillsborough, CA (US)

Correspondence Address:
BOZICEVIC, FIELD & FRANCIS LLP
1900 UNIVERSITY AVE
SUITE 200
EAST PALO ALTO, CA 94303 (US)

(21) Appl. No.: **10/490,456**

(22) PCT Filed: **Sep. 20, 2002**

(86) PCT No.: **PCT/US02/30006**

Related U.S. Application Data

(60) Provisional application No. 60/326,100, filed on Sep. 28, 2001.

Publication Classification

(51) **Int. Cl.**[7] **A61K 38/21**; A61K 31/7056

(52) **U.S. Cl.** **424/85.7**; 514/43

(57) **ABSTRACT**

The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relapse. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen.

METHOD FOR TREATING HEPATITIS C VIRUS INFECTION IN TREATMENT FAILURE PATIENTS

FIELD OF THE INVENTION

[0001] This invention is in the field of treating viral infections, and in particular, treating hepatitis C virus infection.

BACKGROUND OF THE INVENTION

[0002] Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Although the numbers of new infections have declined, the burden of chronic infection is substantial, with Centers for Disease Control estimates of 3.9 million (1.8%) infected persons in the United States. Chronic liver disease is the tenth leading cause of death among adults in the United States, and accounts for approximately 25,000 deaths annually, or approximately 1% of all deaths. Studies indicate that 40% of chronic liver disease is HCV-related, resulting in an estimated 8,000-10,000 deaths each year. HCV-associated end-stage liver disease is the most frequent indication for liver transplantation among adults.

[0003] The high prevalence of chronic HCV infection has important public health implications for the future burden of chronic liver disease in the United States. Data derived from the National Health and Nutrition Examination Survey (NHANES III) indicate that a large increase in the rate of new HCV infections occurred from the late 1960s to the early 1980s, particularly among persons between 20 to 40 years of age. It is estimated that the number of persons with long-standing HCV infection of 20 years or longer could more than quadruple from 1990 to 2015, from 750,000 to over 3 million. The proportional increase in persons infected for 30 or 40 years would be even greater. Since the risk of HCV-related chronic liver disease is related to the duration of infection, with the risk of cirrhosis progressively increasing for persons infected for longer than 20 years, this will result in a substantial increase in cirrhosis-related morbidity and mortality among patients infected between the years of 1965-1985.

[0004] Antiviral therapy of chronic hepatitis C has evolved rapidly over the last decade, with significant improvements seen in the efficacy of treatment. Nevertheless, even with combination therapy using pegylated IFN-α plus ribavirin, 40% to 50% of patients fail therapy. These patients are generally referred to as "treatment failure" patients, and include both non-responders (patients in whom viral titer remains high even during therapy) and relapsers (patients in whom viral titers drop initially during therapy, but subsequently rise either during therapy or after treatment has ended). These patients currently have no effective therapeutic alternative. In particular, patients who have advanced fibrosis or cirrhosis on liver biopsy are at significant risk of developing complications of advanced liver disease, including ascites, jaundice, variceal bleeding, encephalopathy, and progressive liver failure, as well as a markedly increased risk of hepatocellular carcinoma.

[0005] Type I interferons are cytokines that exhibit both antiviral and antiproliferative activity. Type I interferons include interferon-α (IFN-α) and interferon-β. IFN-α [illegible] such as in PEGylated IFN-α. Naturally occurring IFN-α that have been used in anti-viral therapies includes IFN-α2a, IFN-α2b. Derivatives of naturally occurring IFN-α, e.g., PEGylated IFN-α's, have also been used in antiviral therapy.

[0006] Consensus IFN-α's (IFN-con; IFN alfacon; CIFN) are forms of non-naturally occurring type I IFN-α. Consensus interferon alphas include IFN-con$_1$, IFN-con$_2$, and IFN-con$_3$. In vitro studies comparing the relative antiviral, antiproliferative, and natural killer cell activities of recombinant CIFN with either leukocyte or other recombinant type-one interferons demonstrate that CIFN displays significantly higher activity when compared on a mass basis. Others have reported that CIFN, when used in the treatment of diseases susceptible to treatment by alpha interferons, does not cause the same degree of side effects in patients as do the alpha interferons. It has also been reported that 3 to 5 times higher doses of CIFN can be used, leading to enhanced therapeutic benefit, with substantially no corresponding increase in the frequency or severity of undesirable side effects. Some success has been reported in the use of CIFN monotherapy to treat patients that failed to respond to IFN-α therapy.

[0007] Even in view of the therapies currently available, there remains a need for improved therapies for treatment failure patients. The present invention addresses this need.

[0008] Literature

[0009] U.S. Pat. No. 5,980,884. U.S. Pat. No. 5,372,808. Aliaga, S. et al., *Farmacia Clinica* (Spain) 14(5):324-331 (June 1997); Bailly, F. et al., *Nephrol. Dial. Transplant.* 11(Suppl. 4):56-57 (1996); Bizollon, T. et al., *Hepatol.* 26:500-504 (1997); Brillanti, S. et al., *J. Hepatol.* 23(Suppl.2):13-16 (1995); Camps, J. et al., *J. Hepatol.* 19:408-412 (1993); Davis et al., *Hepatol.* 26(Suppl. 1):122S-127S (September 1997); Davis, G. L., *Gastroenterol. Clin. N. Amer.* 23(3):603-613 (1994); Dusheiko, G. M. et al., *Br. Med. J.* 312:357-364 (1996); Fried, M. W., *Med. Clin. N. Anmer.* 80(5):957-972 (1996); Lindsay, K., *Hepatol.* 26(Suppl. 1):71S-77S (September 1997); Mazzaferro, V. et al., *Transplant. Proc.* 29:519-521 (1997); McHutchison, *J., Hepatol.* 26(2):505-506 (August 1997); Merican, M. I., *Med. J. Malaysia* 47(3):158-169 (1992); Poupon, R. and Serfaty, L., *Bull. Acad. Natle. Med.* 180(6):1279-1289 (1996); Reichard, O., *Scand. J. Infect. Dis.* (Suppl. 95):1-56 (1994); Saracco, G. and Rizzetto, M., *Drugs* 53(1):74-85 (1997); Schalm, S. W. and Brouwer, J. T., *Scand. J. Gastroenterol.* 223:46-49 (1997); Schalm, S. W. et al., *Dig. Dis. Sci.* 41(12):131S-134S (December 1996); Scotto, G. et al., *Ital. J. Gastroenterol.* 28:505-511 (1996); Scotto, G. et al., *J. Chemother.* 7(1):58-61 (1995); Theodor, E. and Regev, A., *Harefuah* 132(6):402-403, 447 (1997); Thomas, H. C. et al., *Drugs* 52(Suppl. 2):1-8 (1996); Tillmann, H. and Manns, M., *Kidney Blood Press. Res.* 19(3-4):215-219 (1996); Tong, M. et al., *J. Gastroenterol. Hepatol.* 9:587-591 (1994); Trepo, C. et al., *Nephrol. Dial. Transplant.* 11(Suppl. 4):62-64 (1996); Weiss, R. and Oostrom-Ram, T., *Vet. Microbiol.* 20:255-265 (1989); Chemello, L. et al., *J. Hepatol.* 23(Suppl. 2):8-12 (1995); Main, J., *J. Hepatol.* 23(Suppl. 2):32-36 (1995); Schalm, S. W. et al., *J. Hepatol.* 26:961-966 (May 1997); Sherlock, S., *J. Hepatol.* 23(Suppl. 2):3-7 (1995); Braconier, J. et al., *Scand. J. Infect. Dis.* 27:325-329 (1995); Brillanti, S. et al., *Gastroenterol.* 107:812-817 [illegible]

(2 Jul. 1999); Lai, M-Y. et al., Gastroenterol. 111:1307-1312 (1996); McHutchison, J. G. et al., *N. Eng. J. Med.* 339(21):1485-1491 (1998); Poynard, T. et al., *The Lancet* 352(9138):1426-1432 (1998; Schvarcz, R. et al., *J. Hepatol.* 23(Suppl. 2):17-21 (1995); and Schvarcz, R. et al., *J. Med. Virol.* 46(1):43-47 (1995)

[0010] Melian and Plosker (2001) *Drugs* 61:1-31; Heathcote et al. (1998) *Hepatol.* 27:1136-1143; Heathcote et al. (1999) *Hepatol.* 30:562-566; Sjögren et al. (Apr. 30, 2000) 35th *Annual Meeting of the European Association for the Study of the Liver Rotterdam*; Chow et al. (1998) *Hepatol.* 27:1144-1148; Chemello et al. (1997) *C. Gastroenterol.* 113:1654-1659; Davis et al. (1998) *N. Engl. J. Med.* 339:1493-1499; Kaiser et al. (Apr. 20, 2001) 36th Annual Meeting of the European Association for the Study of the Liver, Prague; Sjögren (Apr. 20, 2001) 36th Annual Meeting of the European Association for the Study of the Liver, Prague.

SUMMARY OF THE INVENTION

[0011] The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relapse. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen.

[0012] In one aspect, the invention features a method for treating a hepatitis C virus infection in an individual. The methods generally involve delivery of CIFN and ribavirin, where CIFN is administered in a therapeutic regimen comprising a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN, where the lowest average daily serum concentration of CIFN achieved by the first dosing regimen is greater than the highest average daily serum concentration of CIFN achieved by the second dosing regimen. Ribavirin is administered during administration of at least the last dosing event of the second dosing regimen, and may be administered with additional dosing events continuous with the last dosing event during which ribavirin is administered. The individual treated has failed previous IFN-α-based therapy, e.g., the individual has either failed to respond to IFN-α therapy other than CIFN therapy, or, following cessation of IFN-α therapy other than CIFN therapy, has suffered a relapse.

Definitions

[0013] The term "treatment failure patients" (or "treatment failures") as used herein generally refers to HCV-infected patients who failed to respond to previous therapy for HCV (referred to as "non-responders") or who initially responded to previous therapy (e.g., in whom an initial viral response (IVR) was observed), but in whom the therapeutic response was not maintained (referred to as "relapsers"). The previous therapy generally can include treatment with IFN-α monotherapy, or IFN-α combination therapy, where the IFN-α combination therapy may include administration of IFN-α and an antiviral agent such as ribavirin.

[0014] The terms "non-CIFN IFN-α" and "IFN-α other than CIFN," used interchangeably herein, refer to IFN-α that is not consensus CIFN and includes, but is not limited to, IFN-α2a; IFN-α2b; IFN-α2C; recombinant forms of naturally-occurring IFN-α, mixtures of naturally occurring IFN-α (e.g., IFN-αn1 and IFN-αn3); and derivatives, e.g., PEGylated derivatives, of the foregoing. The term specifically excludes consensus IFN-α, as defined below.

[0015] The terms "non-CIFN IFN-α" and "IFN-α other than CIFN," used interchangeably herein, refer to IFN-α that is not consensus CIFN and includes, but is not limited to, IFN-α2a; IFN-α2b; IFN-α2C; recombinant forms of naturally-occurring IFN-α, mixtures of naturally occurring IFN-α (e.g., IFN-αn1 and IFN-αn3); and derivatives, e.g., PEGylated derivatives, of the foregoing. The term specifically excludes consensus IFN-α, as defined below.

[0016] The term "consensus IFN-α" (used interchangeably herein with "CIFN" and "IFN-alpha con"), as used herein refers specifically to a synthetic interferons including IFN-con$_1$, IFN-con$_2$, IFN-con$_3$, and derivatives thereof, e.g., PEGylated derivatives. PEGylated derivatives of CIFN can be produced according to methods in the art (see, e.g., U.S. Pat. Nos. 5,985,265; 5,382,657; 5,559,213; and 6,177,074).

[0017] The term "early viral response," used interchangeably with "initial viral response" ("IVR") refers to the drop in viral titer within about 24 hours, about 48 hours, about 2 days, or about 1 week after the beginning of treatment for HCV infection.

[0018] The term "sustained viral response" (SVR; also referred to as a "sustained response" or a "durable response"), as used herein, refers to the response of an individual to a treatment regimen for HCV infection, in terms of serum HCV titer. Generally, a "sustained viral response" refers to no detectable HCV RNA (e.g., less than about 500, less than about 200, or less than about 100 genome copies per milliliter serum) found in the patient's serum for a period of at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, or at least about six months following cessation of treatment.

[0019] As used herein, the terms "treatment,""treating," and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease. "Treatment," as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease (as in liver fibrosis that can result in the context of chronic HCV infection); (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.

[0020] The terms "individual,""host,""subject," and "patient" are used interchangeably herein, and refer to a mammal, including, but not limited to, primates, including simians and humans, with humans being of particular interest.

[0021] Before the present invention is further described, it

vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0022] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0024] It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a dose" includes a plurality of such doses and reference to "the method" includes reference to one or more methods and equivalents thereof known to those skilled in the art, and so forth.

[0025] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

DETAILED DESCRIPTION OF THE INVENTION

[0026] The present invention provides methods of treating hepatitis C virus (HCV) infection in individuals having an HCV infection and have failed treatment, e.g., individuals who have failed to respond to IFN-α therapy other than consensus interferon (CIFN) therapy; or who, during or following cessation of IFN-α therapy other than CIFN therapy, have suffered a relapse. The methods generally involve administration of CIFN and an antiviral agent such as ribavirin as follows: 1) administering a first dosing regimen of CIFN, optionally with a dosing regimen of ribavirin; 2) followed by a second dosing regimen of CIFN and a dosing regimen of ribavirin. The lowest average daily serum concentration of CIFN achieved by the first dosing regimen is higher than the highest average daily serum concentration of CIFN achieved by the second dosing regi-

[0027] The first dosing regimen of CIFN (also referred to as "the induction regimen") generally involves administration of CIFN at about 9 μg, about 15 μg, about 18 μg, or about 27 μg. The first dosing regimen can encompass a single dosing event, or at least two or more dosing events.

[0028] The first dosing regimen of CIFN can be administered daily, every other day, three times a week, or substantially continuously so as to achieve a desired average daily serum concentration of CIFN.

[0029] The first dosing regimen of CIFN (which may be administered in combination with an antiviral such as ribavirin) is administered for a first period of time, which time period can be at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks.

[0030] The first dosing regimen of CIFN (optionally administered with ribavirin) is effective to reduce viral titer to a low viral titer, e.g., a reduction of at least about 0.5 log, at least about 1.0 log, at least about 1.5 log, at least about 2.0 log, at least about 2.5 log, at least about 3.0 log, at least about 3.5 log, at least about 4.0 log, at least about 4.5 log, or at least about 5 log, compared to the pre-treatment viral titer, is achieved by the end of the first dosing regimen.

[0031] The second dosing regimen of CIFN (also referred to as "the maintenance dose") generally involves administration of at least about 3 μg, at least about 9 μg, at least about 15 μg, or at least about 18 μg of CIFN. The second dosing regimen can encompass a single dosing event, or at least two or more dosing events.

[0032] The second dosing regimen of CIFN can be administered daily, every other day, three times a week, or substantially continuously so as to achieve a desired average daily serum concentration of CIFN.

[0033] The second dosing regimen of CIFN (in combination with ribavirin) is effective to reduce viral titer still further, e.g., to undetectable levels, e.g., to from about 500 genome copies per ml serum, to less than or about 200 genome copies per ml serum, or to less than or about 100 genome copies per ml serum.

[0034] The second dosing regimen of CIFN is administered for at least about 8 weeks, at least about 12 weeks, at least about 20 weeks, at least about 24 weeks, or at least about 48 weeks.

[0035] The treatment regimen described above (i.e., the first and second dosing regimens) effects a durable response (also referred to as a "sustained response"), e.g., no detectable HCV RNA is found in the patient's serum for a period of at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, or at least about six months following cessation of a treatment regimen as described herein.

[0036] CIFN is administered in combination with an antiviral agent. The antiviral agent can be administered simultaneously in separate formulations; simultaneously in the same formulation; administered in separate formulations and within about 48 hours, within about 36 hours, within about 24 hours, within about 16 hours, within about 12 hours, within about 8 hours, within about 4 hours, within about 2 hours, within about 1 hour, within about 30 minutes,

CIFN and the antiviral agent may be delivered by the same or different routes. The antiviral agent may be delivered in the same or different dosing regimen as the CIFN.

[0037] In one embodiment, patients are treated with a combination of CIFN and ribavirin. Ribavirin, 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, available from ICN Pharmaceuticals, Inc., Costa Mesa, Calif., is described in the Merck Index, compound No. 8199, Eleventh Edition. Its manufacture and formulation is described in U.S. Pat. No. 4,211,771. The invention also contemplates use of derivatives of ribavirin (see, e.g., U.S. Pat. No. 6,277,830). The ribavirin may be administered orally in capsule or tablet form, or in the same or different administration form and in the same or different route as the CIFN. Of course, other types of administration of both medicaments, as they become available are contemplated, such as by nasal spray, transdermally, by suppository, by sustained release dosage form, etc. Any form of administration will work so long as the proper dosages are delivered without destroying the active ingredient.

[0038] Ribavirin is generally administered in an amount ranging from about 30 mg to about 60 mg, from about 60 mg to about 125 mg, from about 125 mg to about 200 mg, from about 200 mg to about 300 gm, from about 300 mg to about 400 mg, from about 400 mg to about 1200 mg, from about 600 mg to about 1000 mg, or from about 700 to about 900 mg per day.

[0039] In some embodiments, ribavirin is administered throughout the entire course of CIFN therapy. Ribavirin is administered with at least the last dosing regimen, and may be administered with the last dosing regimen and any additional dosing regimen within the treatment regimen continuous with the last dosing regimen. For example, where the treatment regimen includes four dosing events, ribavirin is administered with the fourth dose, and may optionally be administered with the third and fourth doses, the second, third, and fourth doses, or with the first, second, third and fourth doses.

[0040] Exemplary, non-limiting treatment regimens include the following.

[0041] Treatment Regimen 1A: 15 μg CIFN/day for eight weeks, followed by 9 μg CIFN/day for 16 weeks to 40 weeks. Ribavirin is administered 1000-1200 mg per day throughout the treatment regimen.

[0042] Treatment Regimen 1B: 15 μg CIFN/day for eight weeks, followed by 9 μg CIFN/day for 16 weeks to 40 weeks. Ribavirin is administered 1000-1200 mg per day for the last 16-40 weeks.

[0043] Treatment Regimen 2A: 15 μg CIFN/day for eight weeks, followed by 15 μg CIFN three times per week (TIW) for 16-40 weeks. Ribavirin is administered 1000-1200 mg per day throughout the treatment regimen.

[0044] Treatment Regimen 2B: 15 μg CIFN/day for eight weeks, followed by 15 μg CIFN three times per week (TIW) for 16-40 weeks. Ribavirin is administered 1000-1200 mg per day for the last 16-40 weeks.

[0045] Treatment Regimen 3A: 27 μg CIFN/day for four weeks, followed by 18 μg CIFN/day for eight weeks, followed by 9 μg CIFN day for 12 weeks, followed by 9 μg CIFN TIW for 24 weeks. Ribavirin is administered 1000-1200 mg per day throughout the treatment regimen.

[0046] Treatment Regimen 3B: 27 μg CIFN/day for four weeks, followed by 18 μg CIFN/day for eight weeks, followed by 9 μg CIFN day for 12 weeks, followed by 9 μg CIFN TIW for 24 weeks Ribavirin is administered 1000-1200 mg per clay beginning with the eight week course of 18 μg CIFN/day and continued for the remainder of the treatment regimen.

[0047] Treatment Regimen 3C: 27 μg CIFN/day for four weeks, followed by 18 μg CIFN/day for eight weeks, followed by 9 μg CIFN/day for 12 weeks, followed by 9 μg CIFN TIW for 24 weeks Ribavirin is administered 1000-1200 mg per day beginning with the 12 week course of 9 μg CIFN/day and continued for the remainder of the treatment regimen.

[0048] Treatment Regimen 3D: 27 μg CIFN/day for four weeks, followed by 18 μg CIFN/day for eight weeks, followed by 9 μg CIFN day for 12 weeks, followed by 9 μg CIFN TIW for 24 weeks Ribavirin is administered 1000-1200 mg per day beginning with the 24 week course of 9 μg CIFN/TIW and continued for the remainder of the treatment regimen.

[0049] Treatment Regimen 4A: 18 μg CIFN/day for four weeks, followed by 9 μg CIFN/day for 20 weeks, followed by 9 μg CIFN TIW for 24 weeks. Ribavirin is administered 1000-1200 mg per day throughout the treatment regimen.

[0050] Treatment Regimen 4B: 18 μg CIFN/day for four weeks, followed by 9 μg CIFN/day for 20 weeks, followed by 9 μg CIFN TIW for 24 weeks. Ribavirin is administered 1000-1200 mg per day beginning with the 20 week course of 9 μg CIFN/day and continued throughout the treatment regimen.

[0051] Treatment Regimen 4C: 18 μg CIFN/day for four weeks, followed by 9 μg CIFN/day for 20 weeks, followed by 9 μg CIFN TIW for 24 weeks. Ribavirin is administered 1000-1200 mg per day beginning with the 24 week course of 9 μg CIFN TIW and continued throughout the treatment regimen.

[0052] Treatment Regimen 5A: 9 μg CIFN/day for 8-12 weeks, followed by 9 μg CIFN three times a week for the balance of the treatment period (e.g., 36 to 40 weeks), wherein the treatment period is a total of 48 weeks. Ribavirin is administered 1000-1200 mg per day throughout the treatment regimen.

[0053] Treatment Regimen 5B: 9 μg CIFN/day for 8-12 weeks, followed by 9 μg CIFN three times a week (TIW) for the balance of the treatment period (e.g., 36 to 40 weeks), wherein the treatment period is a total of 48 weeks. Ribavirin is administered 1000-1200 mg per day beginning with administration of the treatment course of 9 μg CIFN three times a week and continued throughout the remainder of the treatment regimen.

[0054] Guidance for dosage regimens is found in the art. See, e.g., Kaiser et al. (Apr. 20, 2001) 36th Annual Meeting of the European Association for the Study of the Liver, Prague; Sjögren (Apr. 20, 2001) 36th Annual Meeting of the

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.